Cargando…

Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck Cancer

Vascular disrupting agents (VDAs) represent a relatively distinct class of agents that target established blood vessels in tumors. In this study, we examined the preclinical activity of the second-generation VDA OXi4503 against human head and neck squamous cell carcinoma (HNSCC). Studies were perfor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bothwell, Katelyn D., Folaron, Margaret, Seshadri, Mukund
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728458/ https://www.ncbi.nlm.nih.gov/pubmed/26751478 http://dx.doi.org/10.3390/cancers8010011

Ejemplares similares

Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor
por: Fifis, Theodora, et al.
Publicado: (2013)

Profiling the Stromal and Vascular Heterogeneity in Patient-derived Xenograft Models of Head and Neck Cancer: Impact on Therapeutic Response
por: Folaron, Margaret, et al.
Publicado: (2019)

Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer
por: Kalmuk, James, et al.
Publicado: (2015)

Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis
por: Nguyen, Linh, et al.
Publicado: (2016)

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
por: Cummings, J, et al.
Publicado: (2012)

Editorial to the head and neck cancer—series
por: Seshadri, Mukund
Publicado: (2021)

4503 Adaptation of Motor Action in Children with Hemiplegic Cerebral Palsy
por: Dimitropoulou, Katherine, et al.
Publicado: (2020)

Adrenergic-Angiogenic Crosstalk in Head and Neck Cancer: Mechanisms and Therapeutic Implications
por: Vincent-Chong, Vui King, et al.
Publicado: (2021)

Photoacoustic Imaging as an Early Biomarker of Radio Therapeutic Efficacy in Head and Neck Cancer
por: Rich, Laurie. J., et al.
Publicado: (2018)

Application of Machine Learning Methods to Improve the Performance of Ultrasound in Head and Neck Oncology: A Literature Review
por: DeJohn, Celia R., et al.
Publicado: (2022)

Use of In Vitro and Predictive In Silico Models to Study the Inhibition of Cytochrome P4503A by Stilbenes
por: Basheer, Loai, et al.
Publicado: (2015)

Spatiotemporal Optoacoustic Mapping of Tumor Hemodynamics in a Clinically Relevant Orthotopic Rabbit Model of Head and Neck Cancer()
por: Rich, Laurie J., et al.
Publicado: (2017)

Preclinical Evaluation of Radioiodinated Hoechst 33258 for Early Prediction of Tumor Response to Treatment of Vascular-Disrupting Agents
por: Zhang, Dongjian, et al.
Publicado: (2018)

A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia
por: Uckun, Fatih M., et al.
Publicado: (2019)

Preclinical models in head and neck squamous cell carcinoma
por: Chaves, Patricia, et al.
Publicado: (2023)

A Comprehensive Review of Natural Products as Therapeutic or Chemopreventive Agents against Head and Neck Squamous Cell Carcinoma Cells Using Preclinical Models
por: Liew, Yoon Xuan, et al.
Publicado: (2023)

Enhanced vesicular stomatitis virus (VSVΔ51) targeting of head and neck cancer in combination with radiation therapy or ZD6126 vascular disrupting agent
por: Alajez, Nehad M, et al.
Publicado: (2012)

Vascular disrupting agents in clinical development
por: Hinnen, P, et al.
Publicado: (2007)

Precision Medicine in Head and Neck Cancers: Genomic and Preclinical Approaches
por: Miserocchi, Giacomo, et al.
Publicado: (2022)

Steroid hormones affect binding of the sigma ligand (11)C-SA4503 in tumour cells and tumour-bearing rats
por: Rybczynska, Anna A., et al.
Publicado: (2009)

Sigma-1 Agonist Binding in the Aging Rat Brain: a MicroPET Study with [(11)C]SA4503
por: Ramakrishnan, Nisha K., et al.
Publicado: (2015)

Comparison of Sigma 1 Receptor Ligands SA4503 and PRE084 to (+)-Pentazocine in the rd10 Mouse Model of RP
por: Wang, Jing, et al.
Publicado: (2020)

Demonstrating Tumor Vascular Disrupting Activity of the Small-Molecule Dihydronaphthalene Tubulin-Binding Agent OXi6196 as a Potential Therapeutic for Cancer Treatment
por: Liu, Li, et al.
Publicado: (2022)

Combined magnetic resonance and optical imaging of head and neck tumor xenografts using Gadolinium-labelled phosphorescent polymeric nanomicelles
por: Kumar, Rajiv, et al.
Publicado: (2010)

Vascular disrupting agent induced aggregation of gold nanoparticles for photothermally enhanced tumor vascular disruption
por: Hong, Sheng, et al.
Publicado: (2020)

Vascular anomalies of the head and neck: current overview
por: Lee, Jeong Woo, et al.
Publicado: (2018)

Medical management of vascular anomalies of the head and neck
por: Léauté‐Labrèze, Christine
Publicado: (2022)

Saint John's wort, an herbal inducer of the cytochrome P4503A4 isoform, may alleviate symptoms of Willis-Ekbom's disease
por: Pereira, José Carlos, et al.
Publicado: (2013)

The Reversal Effect of Sigma-1 Receptor (S1R) Agonist, SA4503, on Atrial Fibrillation After Depression and Its Underlying Mechanism
por: Liu, Xin, et al.
Publicado: (2019)

The effect of calcar femoral neck plating on vascularity of the femoral head and neck
por: Kubik, Jeremy F., et al.
Publicado: (2021)

Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4
por: Breslin, Susan, et al.
Publicado: (2017)

Sponge-supported cultures of primary head and neck tumors for an optimized preclinical model
por: Dohmen, Amy J.C., et al.
Publicado: (2018)

Head and Neck Cancer Immunotherapy: Molecular Biological Aspects of Preclinical and Clinical Research
por: Chakraborty, Rajdeep, et al.
Publicado: (2023)

Corrigendum: The Reversal Effect of Sigma-1 Receptor (S1R) Agonist, SA4503, on Atrial Fibrillation After Depression and Its Underlying Mechanism
por: Liu, Xin, et al.
Publicado: (2022)

Risk assessment of drug–drug interaction potential for bintrafusp alfa with cytochrome P4503A4 substrates: A totality of evidence approach
por: Vugmeyster, Yulia, et al.
Publicado: (2022)

Vascular Trauma in the Head and Neck and Endovascular Neurointerventional Management
por: Patel, Jeet, et al.
Publicado: (2020)

Alternative Agents to Prevent Fogging in Head and Neck Endoscopy
por: Piromchai, Patorn, et al.
Publicado: (2011)

Methotrexate, an attractive agent for palliation in head and neck cancers
por: Sharma, Mukesh, et al.
Publicado: (2014)

Development and Validation of a Clinically Relevant Workflow for MR-Guided Volumetric Arc Therapy in a Rabbit Model of Head and Neck Cancer
por: Rajab Bolookat, Eftekhar, et al.
Publicado: (2020)

Drug Metabolism in Human Brain: High Levels of Cytochrome P4503A43 in Brain and Metabolism of Anti-Anxiety Drug Alprazolam to Its Active Metabolite
por: Agarwal, Varsha, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_beupfd0o1g33uma98o9i5vtbnr